T HE OCULAR histoplasmosis syndrome (OHS) has typically included atrophic chorioretinal lesions, peripapillary scarring, and the absence of vitreal inflammation. [1] [2] [3] [4] Choroidal neovascularization is the common cause of loss of vision in involved eyes and is estimated to occur in up to 5% of affected eyes. 3, 5 Gass and Wilkinson 4 have reported that patients observed for an extended period can demonstrate enlargement of previous scars and even the development of new ones. Palvolgyi et al 6 have shown in a primate model of OHS that inflammatory lesions can reactivate. The Macular Photocoagulation Study Group 7 recently reported the results of a 5-year follow-up of fellow eyes in patients with OHS. In a retrospective review of photographs before the development of choroidal neovascularization, "atypical" histoplasmosis lesions were noted. It is unclear what these atypical spots represent. This report provides an extended follow-up of patients with OHS who had an acute reactivation of presumed inflammatory loci.
RESULTS
The Table shows the characteristics of the patients. The mean age was 50.1 years (range, 16-74 years). Of the 12 patients, 7 were women. The patients had a documented diagnosis of OHS for a mean of 10.9 years (range, 1.1-28.7 years). The mean follow-up of the study was 2.1 years (range, 0.9-3.7 years).
The mean acuity on presentation was 20/100 (range, 20/20-20/400) in the affected eye. The mean final acuity in the affected eye was 20/60 (range, 20/20-20/ 400). Seven patients had more than 2 lines of improvement in their acuity, and 4 patients maintained good acuity in the affected eye with resolution of their symptoms. Only 1 patient (patient 5) lost significant acuity during the study. This patient initially improved, but 5 months later his symptoms recurred and a lesion developed into a typical subfoveal neovascular membrane during a 3-month period.
The mean acuity in the fellow eye was 20/170. Each of the decreased acuities in the fellow eye was from previous choroidal neovasculariation.
Of the 12 patients, 6 had myopia. Eight of the patients had only 1 episode during the follow-up. Three patients had 2 separate episodes during the follow-up, and 1 patient had 3 separate episodes.
Of the 12 patients, 7 had a history of onychomycosis or recurrent vaginal yeast
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Associates, Arlington. infections. Because of this, they were treated with itraconazole. Of these 7 patients, 3 were treated with oral prednisone at the beginning of their course before being seen by us; the steroid dosage was rapidly tapered. The remaining 5 patients without a history of systemic fungal infection were also treated with itraconazole because they did not show a prompt response to steroid administration or had previously lost vision in the fellow eye despite corticosteroid treatment.
Six patients had documented evidence that the active inflammatory lesion had been present previously as an inactive scar. 
PATIENTS AND METHODS
All patients with OHS who were seen with new symptoms between August 13, 1993, and November 25, 1995, and who did not have typical neovascular membranes were included in the study. Twelve patients with a minimum follow-up of 6 months are included in this report. In each case, the patients had acute symptoms of decreased vision or metamorphopsia. A detailed clinical history was obtained, visual acuity was measured, and an examination of dilated eyes was performed. None of the patients reported peripheral photopsias that could be associated with other inflammatory diseases. The patients' best Snellen acuity with either their current refraction or pinhole acuity was recorded on each visit. An afferent pupillary defect was not noted in any of the patients. In all patients there were typical punched-out atrophic chorioretinal lesions as well as peripapillary chorioretinal atrophy. In addition, none of the patients had vitreous cells as determined by slitlamp examination with a Hruby lens or 90-diopter lens. Each of the patients demonstrated at least 1 active lesion that showed progressive leakage with irregular borders on angiography. The lesions did not resemble typical welldefined neovascular membranes; they lacked a branching network of vessels, early choroidal fluorescence, subretinal hemorrhage, or increased pigmentation. The optic nerve did not show any signs of active inflammation such as leakage or staining. Routine visual field testing was not done. Indocyanine green angiography and electrophysiologic testing were also not done on a routine basis.
The follow-up consisted of monitoring visual acuity, symptoms, clinical appearance, and fluorescein sodium angiography as indicated.
Of the 12 patients, 6 had been placed on a regimen of oral corticosteroids before being seen by us. The dosage was rapidly tapered in all cases. All 12 patients received a course of oral itraconazole, an antifungal medication.
Informed consent was obtained from all patients in the study. tient later reported that a chronic fungal infection of the toenails had cleared while he was taking the itraconazole. Figure 1 , F through H, shows the color and angiographic appearance 3 months after onset. There is no longer any evidence of active inflammation. Acuity was 20/80 OD and 20/20 OS. Five patients had no previous photographs to determine whether the active spot had been present previously. One patient (patient 5) had photographic and angiographic evidence that the inflammatory lesion was new. (Figure 2, C-F) . The new lesion in the right eye was poorly defined and did not resemble a typical neovascular membrane. A regimen of itraconazole, 100 mg twice a day, was started. During the next month, the patient had improvement of his vision to 20/30. The dosage of itraconazole was decreased to 100 mg/d. In December 1995 the patient thought his vision was stable, and his acuity measured 20/25+2. The itraconazole was stopped. Three months later, a classic subfoveal neovascular membrane developed in the right eye. Acuity decreased to ARCH OPHTHALMOL / VOL 116, APR 1998 473
